Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 3/20 | 0.35 |
| ▸ | CA2 | P00918 | 3/20 | 0.35 |
| ▸ | CA9 | Q16790 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | TERT | O14746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL469795 | 0.86 | TSHR (0.33) | TSHRTDP1MAPTSMN1; SMN2 | |
| SCHEMBL16558118 | 0.84 | TSHR (0.36) | TSHRTDP1MAPTALOX15USP2 | |
| SCHEMBL2741119 | 0.80 | TDP1 (0.64) | TSHRTDP1MAPTALOX15USP2 | |
| SCHEMBL2338559 | 0.74 | MAPT (0.66) | TSHRTDP1MAPTALOX15USP2 | |
| SCHEMBL11686007 | 0.70 | LMNA (0.61) | TSHRTDP1MAPTALOX15USP2 | |
| SCHEMBL14301471 | 0.70 | TSHR (0.54) | TSHRTDP1MAPTALOX15USP2 | |
| Meladrazine SCHEMBL25913 | 0.69 | TSHR (0.47) | TSHRTDP1MAPTALOX15USP2 | |
| SCHEMBL18055624 | 0.68 | TDP1 (0.46) | TSHRTDP1MAPTALOX15USP2 | |
| SCHEMBL2623089 | 0.68 | TSHR (0.52) | TSHRTDP1MAPTALOX15USP2 | |
| SCHEMBL2339204 | 0.68 | MAPT (0.60) | TSHRTDP1MAPTALOX15USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221960-B2 | Multifunctional melamine epoxy resins, methylols and amines | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150073103-A1 | MULTIFUNCTIONAL MELAMINE EPOXY RESINS, METHYLOLS AND AMINES | CRESTLINE DIRECT FINANCE, L.P. | 2015-03-12 | — | — | US | disclosed |
| US-8911858-B2 | Multifunctional melamine epoxy resins, methylols and amines | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-12-16 | — | — | US | disclosed |
| US-20140179838-A1 | MULTIFUNCTIONAL MELAMINE EPOXY RESINS, METHYLOLS AND AMINES | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2014-06-26 | — | — | US | disclosed |
| US-20120063976-A1 | METHODS OF REMOVING CARBON DIOXIDE AND SORBENTS FOR SAME | BATTELLE ENERGY ALLIANCE, LLC (US) | 2012-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179838-A1 | MULTIFUNCTIONAL MELAMINE EPOXY RESINS, METHYLOLS AND AMINES | PNMT, HNMT, NNMT | TSHR 2435/4885TDP1 2104/4885MAPT 2053/4885 |
| US-20150073103-A1 | MULTIFUNCTIONAL MELAMINE EPOXY RESINS, METHYLOLS AND AMINES | PNMT, HNMT, NNMT | TSHR 2435/4885TDP1 2104/4885MAPT 2053/4885 |
| US-20120063976-A1 | METHODS OF REMOVING CARBON DIOXIDE AND SORBENTS FOR SAME | CHRM2, CHRM1, CHRM3 | TSHR 587/4885TDP1 3486/4885MAPT 3538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.